Merck and Moderna reported positive results from a late-stage clinical trial of a personalized mRNA cancer vaccine designed to treat melanoma. When administered alongside existing therapies, the vaccine demonstrated the ability to slow both the recurrence of melanoma and its spread to other body parts. The drugmakers did not immediately release comprehensive data from the trial. The announcement represents a potential advancement in the mRNA cancer vaccine field, which gained significant attention following early-stage trial results in 2024 that marked a turning point for the research area.
In separate health policy developments, questions have emerged regarding diversity, equity, and inclusion requirements in public health education. An accrediting body for the country’s public health schools is considering removing a requirement that schools teach about structural bias, social inequities, and racism. Public health experts have expressed concern about the potential change, characterizing it as anticipatory compliance with the incoming Trump administration. Other observers contend the modification would be appropriate.
A recently published study examined how high-inducing hemp products are marketed on social media. Researchers analyzed over 800 Instagram posts from nine major cannabinoid brands and found that nearly half included youth-oriented imagery and references such as cartoons, celebrities, influencers, and memes. Only 2.5% of the posts displayed health and age warnings. The research comes as Congress included a monthlong delay to a national ban on these hemp products in a recently passed funding bill, with some lawmakers raising concerns about their accessibility to minors.
Meanwhile, scrutiny has intensified around clinical trials in China following recent deaths in gene and cell therapy studies. Three fatal incidents occurred in investigator-initiated trials, which operate under less stringent regulatory oversight than centrally approved pathways. Experts reviewing data from one company conducting a Duchenne muscular dystrophy trial offered divergent assessments of the scientific quality and methodological approach, with opinions ranging from cautious acceptance to significant criticism of the underlying science.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI